Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of Cetuximab + Irinotecan + S-1 as first line therapy in metastatic colorectal cancer with KRAS wild type

ABSTRACT: Interventions: IRIS + Cetuximab Cetuximab loading dose 400mg/m2, 250 mg/m2/week Irinotecan 100 mg/m2/biweekly S-1 80,100,120 mg/twice/day 1-14, following two weeks off Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620027 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer

Project description:Interventions: Surgical hepatectomy followed by chemotherapy (mFOLFOX6) 12cycles. mFOLFOX6(L-OHP 85 mg/m2/biweekly, Levofolinate 200 mg/m2/biweekly, 5-FU/bolus 400 mg/m2/biweekly, 5-FU/continuous 2,400 mg/m2/biweekly) Pre-operative chemotherapy(mFOLFOX6 plus cetuximab) 6cycles followed by surgical hepatectomy followed by post-operative chemotherapy (mFOLFOX6 plus cetuximab) 6cycles. Cetuximab(loading dose 400mg/m2, 250 mg/m2/week), mFOLFOX6(L-OHP 85 mg/m2/biweekly, Levofolinate 200 mg/m2/biweekly, 5-FU/bolus 400 mg/m2/biweekly, 5-FU/continuous 2,400 mg/m2/biweekly) Primary outcome(s): Progression free survival Study Design: Parallel Randomized

| 2623200 | ecrin-mdr-crc

Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: cetuximab loading dose 400mg/m2, 250mg/m2/week L-OHP 85mg/m2/biweekly levofololinate 200mg/m2/biweekly 5-FU bolus 400 mg/m2/biweekly 5-FU continuous 2,400 mgm2/biweekly / cetuximab loding dose 400 mg/m2, 250 mg/m2/week L-OHP 75-130 mg/m2/tri-weekly S-1 80-120 mg/day, day1-14 Primary outcome(s): Correlation between the reported biomarkers (EGFR expression, ligand expression to EGFR, BRAF, PI3K, and PTEN expression) or new ones (DNA microarray, analysis of microRNA expression, and DNA SNP analysis) and the response to cetuximab containing combination therapies Study Design: Parallel Randomized

| 2626017 | ecrin-mdr-crc

Phase II Study of FOLFOX + Erbitux as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

Project description:Interventions: mFOLFOX6+cetuximab Cetuximab loading dose 400mg/sqm,250 mgsqm/week L-OHP 85 mg/sqm/biweekly Levofolinate 200 mg/sqm/biweekly 5-FU bolus 400 mg/sqm/biweekly 5-FU continuous 2,400 mg/sqm/biweekly Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2619647 | ecrin-mdr-crc

Study of Bevacizumab + Irinotecan + S-1 therapy in metastatic colorectal cancer with KRAS mutant type

Project description:Interventions: IRIS + Bevacizumab Bevacizumab 5mg/kg/biweekly Irinotecan 100 mg/m2/biweekly S-1 80,100,120 mg/twice/day 1-14, following two weeks off Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2620076 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer

Project description:A single-central,open-label,safety,pharmacokinetics,phase I study. Biological:Recombinant Anti-EGFr Antibody Two dose levels: Low-dose level patients received initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.

| 2233985 | ecrin-mdr-crc

Multicenter PhaseII study of Combination FOLFIRI with Erbitux in advanced/metastatic colorectal cancer: EGFR positive and KRAS wild type

Project description:Interventions: FOLFIRI (CPT-11, 5-FU bolus, 5-FU infusional, l-LV)+ Erbitux Cetuximab 400 mg/m2(day1) Cetuximab 250 mg/m2/week, (except day 1) CPT-11 100 or 150 mg/m2/bi-week l-LV 200 mg/m2/bi-week 5-FU/bolus 400 mg/m2/bi-week 5-FU/infusional2,400 mg/m2/bi-week (day 1-3) Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2617576 | ecrin-mdr-crc

Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer

Project description:Interventions: Capecitabine+oxaliplatin(XELOX)+Cetuximab Cetuximab loading dose 400mg/m2, 250mg/m2/week or 500mg/m2/2weeks Capecitabine 2000mg/m2(day1-7)/2weeks Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2622614 | ecrin-mdr-crc

Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)

Project description:Interventions: Irinotecan 150 mg/m2/biweekly div l-LV 200mg/m2/biweekly div 5-FU/bolus 400mg/m2/biweekly div (bolus) 5-FU/infusional 2,400mg/m2/biweekly div Panitumumab 6mg/kg/biweekly div or S-1 80mg/m2/day p.o. day 1-7 Irinotecan 150mg/m2 day 1 Panitumumab 6mg/kg/biweekly div Irinotecan 150mg/m2/ biweekly div Panitumumab 6mg/kg/biweekly div Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

| 2623074 | ecrin-mdr-crc

Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)

Project description:Interventions: Irinotecan plus S-1 (IRSI) with biweekly cetuximab combination therapy 1)Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD 2)S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks 3)Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2622245 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data